Dyne Historical Cash Flow
| DYN Stock | USD 31.13 1.90 6.50% |
Analysis of Dyne Therapeutics cash flow over time is an excellent tool to project Dyne Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Working Capital of 17.4 M or Begin Period Cash Flow of 165.7 M as it is a great indicator of Dyne Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Dyne Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Dyne Therapeutics is a good buy for the upcoming year.
Dyne |
About Dyne Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Dyne balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Dyne's non-liquid assets can be easily converted into cash.
Dyne Therapeutics Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Dyne Therapeutics financial statement analysis. It represents the amount of money remaining after all of Dyne Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Investments
Securities or assets acquired for generating income or appreciating in value, not used in daily operations.Most accounts from Dyne Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Dyne Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.At this time, Dyne Therapeutics' Change To Netincome is very stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Change To Netincome | 19.4M | 18.2M | 20.9M | 21.9M | Issuance Of Capital Stock | 157.2M | 36.9M | 89.2M | 126.9M |
Dyne Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Dyne Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Dyne Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 6.5M | 288.5M | (99.6M) | (29.1M) | (50.5M) | (53.1M) | |
| Stock Based Compensation | 26K | 6.6M | 17.5M | 15.2M | 20.0M | 21.0M | |
| Free Cash Flow | (13.5M) | (47.7M) | (123.2M) | (156.7M) | (188.9M) | (179.4M) | |
| Change In Working Capital | 1.4M | 5.1M | 9.3M | (5.4M) | 26.3M | 17.4M | |
| Begin Period Cash Flow | 8.1M | 14.6M | 303.2M | 203.5M | 174.5M | 165.7M | |
| Other Cashflows From Financing Activities | 20.0K | 134.4M | 584K | 529K | 3.9M | 3.7M | |
| Depreciation | 271K | 700K | 1.1M | 1.7M | 571K | 542.5K | |
| Other Non Cash Items | 1.3M | 514K | (746K) | 3.0M | 929K | 882.6K | |
| Capital Expenditures | 1.6M | 1.2M | 3.6M | 3.1M | 729K | 692.6K | |
| Total Cash From Operating Activities | (11.8M) | (46.5M) | (119.6M) | (153.6M) | (188.2M) | (178.8M) | |
| Net Income | (14.9M) | (59.4M) | (149.3M) | (168.1M) | (235.9M) | (247.7M) | |
| Total Cash From Financing Activities | 20.0M | 380.7M | 157.8M | 37.4M | 54.3M | 51.6M | |
| End Period Cash Flow | 14.6M | 303.2M | 203.5M | 174.5M | 123.9M | 117.7M | |
| Investments | (1.6M) | (45.7M) | (134.3M) | 87.2M | 76.4M | 80.2M | |
| Total Cashflows From Investing Activities | (1.6M) | (45.7M) | (137.9M) | 87.2M | 100.3M | 105.3M | |
| Change To Operating Activities | (284K) | (3.5M) | (4.4M) | (4.1M) | (3.7M) | (3.9M) | |
| Issuance Of Capital Stock | 20.0M | 381.2M | 157.2M | 36.9M | 89.2M | 126.9M | |
| Change To Netincome | 1.3M | 7.1M | 19.4M | 18.2M | 20.9M | 21.9M | |
| Change To Liabilities | 1.7M | 8.6M | 13.7M | (1.2M) | (1.4M) | (1.3M) |
Pair Trading with Dyne Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dyne Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dyne Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Dyne Stock
| 0.7 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Dyne Stock
| 0.62 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.58 | PHVS | Pharvaris BV | PairCorr |
| 0.53 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.36 | PMVP | Pmv Pharmaceuticals | PairCorr |
| 0.32 | MNOV | MediciNova | PairCorr |
The ability to find closely correlated positions to Dyne Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dyne Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dyne Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dyne Therapeutics to buy it.
The correlation of Dyne Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dyne Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dyne Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Dyne Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyne Therapeutics. If investors know Dyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.58) | Return On Assets (0.40) | Return On Equity (0.69) |
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.